Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.15873 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Salomé Martin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regional Centre of Pharmacovigilance and Pharmacoepidemiology, Reims University Hospital, 51100, Reims, France. Hauptthemen laut MEDLINE: Sweet Syndrome, Pharmacovigilance, Databases, Factual, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Sweet's syndrome is an acute febrile neutrophilic dermatosis first described in 1964 by Robert Douglas Sweet. The pathophysiological mechanism is not fully established; however, several cases of Sweet's syndrome have been reported following drug administration.
Methods
To investigate the existence of pharmacovigilance signals between drugs and the occurrence of Sweet's syndrome, we performed a case/non‐case study on reports of ‘acute febrile neutrophilic dermatosis’ registered in the French pharmacovigilance database. Reporting odds ratio (ROR) with its 95% confidence interval were calculated.
Results
Amongthe 994 789 reports recorded in the database, 136 were Sweet's syndrome, of which 50.7% were men and the median age was 59 years (range 15–91). A total of 224 drugs were mentioned as suspects: 21.0% were antibacterials, 19.2% were antineoplastics and 12.1% were immunosuppressants. Median time to onset from drug initiation to the development of Sweet's syndrome was 15 days (range 1–1095). The highest RORs were observed with bortezomib (74.04 [40.8–134.2]), azacitidine (72.14 [29.4–176.9]), perfilgrastim (67.05 [21.2–211.6]), azathioprine (55.46 [34.8–88.4]) and bendamustine (35.84 [11.4–112.8]).
Conclusions
Pharmacovigilance signals have been observed between the occurrence of Sweet's syndrome and colony‐stimulating factors, immunosuppressants, antineoplastics and antibiotics. Clinicians should be aware of the potential associations with these drugs and should be encouraged to report any case of drug‐induced Sweet's syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Centre of Pharmacovigilance and Pharmacoepidemiology, Reims University Hospital, 51100, Reims, France.
- Regional Centre of Pharmacovigilance and Pharmacoepidemiology, Rouen University Hospital, 76000, Rouen, France.
- Regional Centre of Pharmacovigilance and Pharmacoepidemiology, Lyon University Hospital, 69495, Lyon, France.
ORCID-Profile: Salomé Martin, Thierry Trenque, Brahim Azzouz
Zitieren
APA
Martin, S., Trenque, T., Herlem, E., Boulay, C., Pizzoglio, V., & Azzouz, B. (2024). Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15873
Vancouver
Martin S, Trenque T, Herlem E, Boulay C, Pizzoglio V, Azzouz B. Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15873
BibTeX
@article{Martin2024,
author = {Martin, Salomé and Trenque, Thierry and Herlem, Emmanuelle and Boulay, Charlène and Pizzoglio, Véronique and Azzouz, Brahim},
title = {Drug‐induced Sweet's syndrome: A case/non‐case study in the French pharmacovigilance database},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.15873}
}
EUVIMED